Skip to content

Rhadar-RhePort healthcare model: Improvement in Rheumatoid Patient Care I und II

Rhadar-RhePort healthcare model: Improvement in Rheumatoid Patient Care I und II - IRPIC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00035852
Enrollment
1500
Registered
2025-01-21
Start date
2025-02-19
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with rheumatic complaints in a broader sense prior to diagnosis M00-M99 L40

Interventions

Group 1: RhePort-Cohort: New patients receive their initial appointment scheduled through RhePort. Medical data is collected, including the diagnosis, disease activity, and pain activity, as well as d

Sponsors

RheumaDatenRhePort (Rhadar) GbR
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: new appointments in the corresponding rheumatology center publicly health-insured no confirmed diagnosis of an inflammatory rheumatic disease

Exclusion criteria

Exclusion criteria: insured through private health insurance

Design outcomes

Primary

MeasureTime frame
Proportion of diagnoses for inflammatory rheumatic vs. non-inflammatory rheumatic diseases in the cohort of New Patients

Secondary

MeasureTime frame
• Duration from first appointment request to actual appointment, depending on the different appointment scheduling systems (e.g., RhePort, GP-mediated appointments) • Exploratory investigation: Examining a potential correlation between the score assigned by RhePort and indication-specific disease activity scores or assessments • Examining the difference in indication-specific disease activity scores between the RhePort cohort and the non-RhePort cohort • Proportion of correctly identified positive patients (patients with an inflammatory rheumatic diagnosis vs. non-inflammatory) through RhePort

Countries

Germany

Contacts

Public ContactSarah Wildenhain

Libertamed GmbH

sarah.wildenhain@libertamed.de+49 414144084

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026